GSK to shift consumer media business by end of Feb.

Share this article:
GSK to shift consumer media business by end of Feb.
GSK to shift consumer media business by end of Feb.
GlaxoSmithKline should be finished transitioning the media planning and buying for its North American OTC business by the end of February, a spokesperson for the drugmaker said. The benefactor of the switch, WPP shop MediaCom, already handles buying and planning tasks for GSK's North American prescription-drug business.

Malesia Dunn, GSK director of communications, said the shift was simply a business decision to allow for greater efficiency.

Media for the OTC brands—which include Panadol, Aquafresh, Lucozade and Nicorette—had been split among MediaCom, Havas' MPG, Publicis' Optimedia and Campbell Mithun.

Notably, last year GSK moved all of its professional advertising business in the opposite direction, from WPP agencies to IPG ones, including Draftfcb Healthcare and Lowe Healthcare's Integrated Communications unit.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...